Skip to content

The study of esketamine intravenous anesthesia in minimally invasive rotational mastectomy

The study of esketamine intravenous anesthesia in minimally invasive rotational mastectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080406
Enrollment
Unknown
Registered
2024-01-29
Start date
2024-02-01
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast masses

Interventions

PE:Propofol combined with esketamine are used for intravenous anesthesia
PS:Propofol combined with sufentanil are used for intravenous anesthesia

Sponsors

People's Hospital of Ningxia Hui Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1: ASA I-?; 2: Age 18-65 years; 3: BIM 18~29.9 kg/m2; 4: Patients undergoing minimally invasive rotational mastectomy; 5: All patients obtained informed consent before surgery and volunteered to participate in this study.

Exclusion criteria

Exclusion criteria: 1: Patients who have allergic to planned used drugs; 2: Patients with a history of uncontrolled or malignant hypertension or severe ischemic heart disease; 3: Patients with hyperthyroidism; 4: Patients with psycho-nervous system diseases; 5: Patients with a history of chronic pain and drug abuse; 6: Pregnant patients and patients with sleep apnea hypopnea syndrome; 7: Patients who have taken within 48 hours before surgery or are taking opioids and non-steroidal anti-inflammatory drugs.

Design outcomes

Primary

MeasureTime frame
The incidence of low oxygen saturation or hypotension or both;VAS score of nausea and vomiting;

Secondary

MeasureTime frame
The incidence of intraoperative body movement;Postoperative recovery time;Modified Aldrete score;NRS score of pain level;

Countries

China

Contacts

Public ContactQi xia

People's Hospital of Ningxia Hui Autonomous Region

18295517863@163.com+86 181 6157 5709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026